2Pitt B,Segal R.Martinez FA,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).Lancet, 1997,349:747-752.
3Pitt B,Poole-Wilson PA,Segal R,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.Lancet, 2000,355:1582-1587.
4Daholof B,Devereux RB,Kjeldsen SE,et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet,2002,359:995-1003.
5Lewis EJ,Hunsicker LG,Clarke WR,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med, 2001,345:851-860.
6Circulation, 2002;106:672.
7Parving HH,Lehnert H,Brochner-Mortensen J,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N Engl J Med, 2001,345:870-878.
8Brenner BM,Cooper ME,de Zeeuw D,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med. 2001 Sep 20;345(12):861-869.
9Lithell H,Hansson L,Skoog I,et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.J Hypertens, 2003,21:875-886.
10ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Groop. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lo
